EP0915969A4 - SUPPRESSION OF CD4 + CELL INFECTION BY HIV - Google Patents

SUPPRESSION OF CD4 + CELL INFECTION BY HIV

Info

Publication number
EP0915969A4
EP0915969A4 EP97917856A EP97917856A EP0915969A4 EP 0915969 A4 EP0915969 A4 EP 0915969A4 EP 97917856 A EP97917856 A EP 97917856A EP 97917856 A EP97917856 A EP 97917856A EP 0915969 A4 EP0915969 A4 EP 0915969A4
Authority
EP
European Patent Office
Prior art keywords
infection
cells
preventing hiv
hiv
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP97917856A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0915969A1 (en
Inventor
Graham P Allaway
Virginia M Litwin
Paul J Maddon
William C Olson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Progenics Pharmaceuticals Inc
Original Assignee
Progenics Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharmaceuticals Inc filed Critical Progenics Pharmaceuticals Inc
Publication of EP0915969A1 publication Critical patent/EP0915969A1/en
Publication of EP0915969A4 publication Critical patent/EP0915969A4/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/195—Chemokines, e.g. RANTES
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP97917856A 1996-04-02 1997-04-02 SUPPRESSION OF CD4 + CELL INFECTION BY HIV Ceased EP0915969A4 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US62768496A 1996-04-02 1996-04-02
US627684 1996-04-02
US66361696A 1996-06-14 1996-06-14
US663616 1996-06-14
US67368296A 1996-06-25 1996-06-25
US673682 1996-06-25
PCT/US1997/005597 WO1997037005A1 (en) 1996-04-02 1997-04-02 Method for preventing hiv-1 infection of cd4+ cells

Publications (2)

Publication Number Publication Date
EP0915969A1 EP0915969A1 (en) 1999-05-19
EP0915969A4 true EP0915969A4 (en) 2002-04-17

Family

ID=27417425

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97917856A Ceased EP0915969A4 (en) 1996-04-02 1997-04-02 SUPPRESSION OF CD4 + CELL INFECTION BY HIV

Country Status (5)

Country Link
EP (1) EP0915969A4 (enExample)
JP (2) JP2000507596A (enExample)
AU (1) AU728512B2 (enExample)
CA (1) CA2250829A1 (enExample)
WO (1) WO1997037005A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US7118859B2 (en) 1996-01-17 2006-10-10 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US6107019A (en) * 1996-06-14 2000-08-22 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US7858298B1 (en) 1996-04-01 2010-12-28 Progenics Pharmaceuticals Inc. Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists
AU3375697A (en) 1996-05-28 1998-01-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cc chemokine receptor 5, antibodies thereto, transgenic animals
DK0910659T3 (da) * 1996-06-03 2006-11-27 United Biomedical Inc Antistoffer mod et kompleks af CD4 og et kemokin-receptordomæne og anvendelse deraf mod HIV-infektioner
MXPA00003885A (es) * 1997-10-22 2004-04-23 Inst Genetics Llc Quimiocinas con modificiaciones de la terminacion amino.
FR2771423A1 (fr) * 1997-11-21 1999-05-28 Transgene Sa Vecteurs permettant d'inhiber ou retarder la liaison d'un virus d'immunodeficience et/ou sa penetration dans une cellule cible
US6399078B1 (en) 1998-06-01 2002-06-04 University Of Maryland Biotechnology Institute Chemokine—glycosaminoglycan complexes and their use in treating or preventing receptor mediated diseases
AU781934B2 (en) * 1999-07-09 2005-06-23 Gen-Probe Incorporated Detection of HIV-1 by nucleic acid amplification
US6582920B2 (en) 2000-09-01 2003-06-24 Gen-Probe Incorporated Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations
US7138119B2 (en) 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US7060273B2 (en) 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
WO2005105841A2 (en) 2004-03-12 2005-11-10 Human Genome Sciences, Inc. Human g-protein chemokine receptor (ccr5) hdgnr10
EP1910573B1 (en) 2005-07-22 2013-09-04 CytoDyn, Inc. Methods for reducing viral load in hiv-1-infected patients
EP2053060A1 (en) * 2007-10-24 2009-04-29 Protaffin Biotechnologie AG SDF-1-based glyocosaminoglycan antagonists and methods of using same
AU2014312123A1 (en) 2013-08-29 2016-03-17 Temple University Of The Commonwealth System Of Higher Education Methods and compositions for RNA-guided treatment of HIV infection

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028258A1 (en) * 1996-01-30 1997-08-07 The National Institutes Of Health Cells expressing both human cd4 and cxcr4
WO1997044462A1 (fr) * 1996-05-22 1997-11-27 Institut Pasteur Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5440021A (en) * 1991-03-29 1995-08-08 Chuntharapai; Anan Antibodies to human IL-8 type B receptor
US5504003A (en) * 1994-03-08 1996-04-02 Human Genome Sciences, Inc. Macrophage inflammatory protein-3 and -4
US6265184B1 (en) 1995-12-20 2001-07-24 Icos Corporation Polynucleotides encoding chemokine receptor 88C
ATE428785T1 (de) 1996-03-01 2009-05-15 Euroscreen Sa Aktive und inactive cc-chemokinrezeptoren und nukleinsäuremoleküle, die für diesen rezeptor kodieren

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997028258A1 (en) * 1996-01-30 1997-08-07 The National Institutes Of Health Cells expressing both human cd4 and cxcr4
WO1997044462A1 (fr) * 1996-05-22 1997-11-27 Institut Pasteur Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ARENZANA-SEISDEDOS F ET AL: "HIV BLOCKED BY CHEMOKINE ANTAGONIST", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 383, 3 October 1996 (1996-10-03), pages 400, XP002025860, ISSN: 0028-0836 *
F. COCCHI ET AL.: "IDENTIFICATION OF RANTES, MIP-1ALPHA, AND MIP-1BETA AS THE MAJOR HIV-SUPPRESSIVE FACTORS PRODUCED BY CD8+ T CELLS", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE,, US, vol. 270, 15 December 1995 (1995-12-15), pages 1811 - 1815, XP000616644, ISSN: 0036-8075 *
See also references of WO9737005A1 *

Also Published As

Publication number Publication date
JP2000507596A (ja) 2000-06-20
AU728512B2 (en) 2001-01-11
AU2607497A (en) 1997-10-22
JP2008069148A (ja) 2008-03-27
EP0915969A1 (en) 1999-05-19
CA2250829A1 (en) 1997-10-09
WO1997037005A1 (en) 1997-10-09

Similar Documents

Publication Publication Date Title
AU4282996A (en) Mesoscale devices for analysis of motile cells
AU3006197A (en) Dental implant system
AU1811299A (en) Dental implant system and method
AU4926493A (en) Dental implant method
AU3390297A (en) Uses of a chemokine receptor for inhibiting hiv-1 infection
AU1641495A (en) Method for long term subculture of dermal papilla cells
IL106255A0 (en) Method for isolating human blood cells
AU7672296A (en) Method of preparing electrochemical cells
IL136731A0 (en) Method for reducing susceptibility to hiv infection
AU1750497A (en) Compounds capable of inhibiting hiv-1 infection
AU6130196A (en) Cell treatment
HUP9802834A3 (en) Preparations for the treatment of t cell mediated autoimmune diseases
AU4602897A (en) Method for treatment of immunodeficiency virus infection
IL116925A0 (en) Compounds for treating hiv infection
GB9621974D0 (en) HIV integrase inhibitors
AU3553195A (en) Methods of identifying agents which block hiv infection
AU1757297A (en) Protection of hemopoietic cells
AUPM424894A0 (en) Treatment of electrolyte solutions
AU2003200133A1 (en) Method for preventing HIV-1 infection of CD4+ cells
AU2212795A (en) Cochlea implant system
AU1979397A (en) Peptidomimetics for the treatment of hiv infection
AU3698199A (en) Radioimmuno-pharmacon for treating the hiv-1 infection
AU5095996A (en) Interferon-gamma treatment of HLA-DR-associated immunodeficiency
GB9508300D0 (en) HIV protease inhibtors for the treatment of aids
EP0951451A4 (en) AUXILIARY WASTEWATER TREATMENT SYSTEM

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19981102

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: OLSON, WILLIAM, C.

Inventor name: MADDON, PAUL, J.

Inventor name: LITWIN, VIRGINIA, M.

Inventor name: ALLAWAY, GRAHAM, P.

A4 Supplementary search report drawn up and despatched

Effective date: 20020306

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 12N 5/10 A, 7C 07K 16/28 B, 7A 61K 38/19 B, 7A 61K 39/395 B, 7G 01N 33/50 B

17Q First examination report despatched

Effective date: 20030509

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APAX Date of receipt of notice of appeal deleted

Free format text: ORIGINAL CODE: EPIDOSDNOA2E

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APBR Date of receipt of statement of grounds of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA3E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20110125